PD-L1 expression was significantly increased on tumor cells and some immune cells after M1 treatment, as indicated by flow cytometry analysis of PD-L1 expression on CD45− (Fig. 6A) and CD45+ CD3- cells (Fig. 6B). Here, PTPRC is linked to neoplasm.